* Eikon search string for individual stock moves: STXBZ
* The Day Ahead newsletter: tmsnrt.rs/2ggOmBi
* The Morning News Call newsletter: tmsnrt.rs/2fwPLTh U.S. stock index futures were slightly higher on Tuesday as technology shares staged a recovery after a two-day rout, while investors awaited the Federal Reserve to kick off its meeting, where its is almost certain to raise interest rates.
At 8:10 ET, Dow e-minis were up 0.10 percent at 21,248. S&P 500 e-minis were up 0.16 percent at 2,432.5, while Nasdaq 100 e-minis were up 0.33 percent at 5,730. BUZZ-Over to New York-GBP recovers, EUR & USD drift The top three NYSE percentage gainers premarket: ** LG Display Co, up 6.0 pct at $16.50 ** Enzo Biochem Inc, up 5.0 pct at $10.30 ** Tableau Software Inc, up 4.5 pct at $62.94 The top three NYSE percentage losers premarket: ** Cobalt International, down 31.4 pct at $0.16 ** EXCO Resources Inc, down 13.4 pct at $4.20 ** BP Prudhoe Bay Royalty Trust, down 11.3 pct at $18.45 The top three Nasdaq percentage gainers premarket: ** Ability Inc, up 27.4 pct at $1.49 ** Magnegas Corp, up 23.7 pct at $1.72 ** Genocea Biosciences, up 19.9 pct at $6.86 The top three Nasdaq percentage losers premarket: ** Omnicell Inc, down 9.7 pct at $38.70 ** Acceleron Pharma, down 8.8 pct at $25.75 ** GTX Inc, down 6.3 pct at $5.76
** Apple Inc: up 1.1 pct at $147.00 premarket BUZZ-Apple selloff a boon to short sellers ** PSivida Corp: up 7.7 pct at $2.24 premarket BRIEF-Psivida’s Durasert achieves primary efficacy endpoint in second Phase 3 study
** Magnegas Corp: up 23.7 pct at $1.72 premarket BRIEF-Magnegas awarded USDA grant to commercialize sterilization tech ** Alibaba Group Holding Ltd: up 1.9 pct at $141.78 premarket BRIEF-Equinix announces collaboration with Alibaba Cloud
** Sears Canada Inc: up 1.9 pct at $141.78 premarket Sears Canada raises “going concern” doubts ** Cobalt International Energy: down 31.4 pct at $0.16 premarket BRIEF-Cobalt International Energy board approves reverse stock split ** Acceleron Pharma Inc: down 8.8 pct at $25.75 premarket BRIEF-Acceleron says Dart phase 2 study of dalantercept plus axitinib did not achieve its primary endpoint in advanced Renal Cell Carcinoma (Compiled by Gayathree Ganesan in Bengaluru)